NCT05036798Unknown2 期
A Single-arm, Open, Phase II Clinical Study of Tislelizumab Combined With Lenvatinib and Gemox Regimen for Transformational Treatment of Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2021年9月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- R0 resection rate
研究概览
简要总结
This is a single-arm, open, Phase II clinical study of Tislelizumab combined with lenvatinib and Gemox regimen for transformational treatment of potentially resectable locally advanced malignant tumors of biliary system.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological diagnosis of potentially resectable local advanced biliary malignancies (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder carcinoma, ampullary carcinoma);
- •Potential resectable criteria: The first-stage R0 resection cannot be guaranteed for patients with cholangiocarcinoma admitted to our hospital, and there are the following imaging characteristics (satisfy one or more) :
- •The hilar and retroperitoneal lymph nodes were considered for metastasis but could be resected completely.
- •Intrahepatic cholangiocarcinoma has multiple foci, but foci are less than three and limited to half of the liver.
- •Local progression of gallbladder carcinoma with colon or duodenal involvement.
- •Hilar cholangiocarcinoma or lower segment of cholangiocarcinoma involving portal vein or hepatic artery requires combined vascular resection or reconstruction;
- •Patient age 20-79 years;
- •At least one measurable lesion as defined in RECIST version 1.1;
- •ECOG score was 0-1;
- •No prior medical treatment;
- •Adequate organ and bone marrow function and laboratory tests meet the following requirements:
- •NEUT≥1.5×109/L；
- •PLT ≥100×109/L；
- •TBIL≤1.5 times normal upper limit (ULN);
- •ALT and AST ≤2.5 x ULN;ALT and AST≤5×ULN for liver metastasis;
- •Endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula);
- •Urinary protein < (++), or 24 hours urinary protein <1.0 g;
- •Coagulation was normal without active bleeding
- •International standardized ratio INR≤1.5;
- •Partial thrombin time APTT≤1.5 ULN;
- •Women of childbearing age must have a negative pregnancy test (serum or urine) within 14 days prior to enrollment and voluntarily use an appropriate method of contraception during the observation period and within 8 weeks after the last administration of the study drug;For men, surgical sterilization or consent to use appropriate methods of contraception during the observation period and for 8 weeks after the last administration of the study drug;
- •Estimated survival ≥3 months;
- •The patients voluntarily participated in the study and signed the informed consent (ICF);
- •It is expected that patients with good compliance will be able to follow up the efficacy and adverse reactions according to protocol requirements.
- •Tumor tissue samples for PD-L1 expression analysis and microsatellite instability analysis.
排除标准
- •The patient must be excluded from the study if any of the following conditions occur at the time of inclusion:
- •Allergic to known anti-PD-1 and anti-PD-L1 antibodies;
- •Patients with hypertension (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg), grade I or above coronary heart disease, grade I arrhythmia (including prolonged QTc interval > 450 ms in males and > 470 ms in females) and grade I cardiac insufficiency;
- •Risk of biliary obstruction;
- •Allergic to the drugs of the program (gemcitabine, oxaliplatin);
- •Patients with a clear tendency of gastrointestinal bleeding, including the following conditions: local active ulcer lesions, and fecal occult blood (++) cannot be included in the group; Patients with a history of melena and hematemesis within 1 month;
- •Patients with immune system diseases need to take more than 10mg of dexamethasone daily;
- •Patients with concomitant diseases that, according to the judgment of the investigator, seriously endanger the patient's safety or affect the patient's ability to complete the study;
- •The researcher considered it unsuitable for inclusion.
研究组 & 干预措施
Tislelizumab combined with Lenvatinib and GEMOX
Experimental
Chemotherapy regimen(GEMOX):
Gemcitabine 1g/m2,Oxaliplatin 100mg/m, D1, Q3W Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD
Receive at least 3 cycles of combined treatment, and perform imaging evaluation after 3 cycles of treatment. If surgical treatment is not possible, imaging evaluation will be performed every two cycles thereafter until surgical treatment is feasible. If more than 7 cycles are still not possible for surgical resection, enter Tislelizumab + Lenvatinib maintenance treatment until the disease progresses or the toxicity cannot be tolerated.
If patients undergoing R0 resection, start to receive Tislelizumab + Lenvatinib+Gemox regimen in 4-8 weeks after surgery for 7 cycles, and then entered Tislelizumab+Lenvatinib for 1 year or disease progression or toxicity cannot be tolerated
干预措施: Tislelizumab (Drug)
结局指标
主要结局
R0 resection rate
时间窗: 5 months
次要结局
- Improvement in quality of life as measured by the EORTC Quality of Life Questionnaire QLQ-C30 (V3.0)(24 months)
- Disease control rate (DCR)(5 months)
- Objective response rate (ORR)(5 months)
- Progression-free survival (PFS)(18 months)
- Overall survival (OS)(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaResectable Hepatocellular CarcinomaNCT04834986Tianjin Medical University Cancer Institute and Hospital30
Unknown
2 期
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center StudyHigh-Risk Non-Muscle Invasive Bladder Urothelial CarcinomaNCT05418309Tianjin Medical University Second Hospital63
Unknown
2 期
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely ResectableHigh-RiskNon-Muscle Invasive Bladder Urothelial CarcinomaNCT04730232Tianjin Medical University Second Hospital63
招募中
2 期
Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder CancerNCT05620498Tianjin Medical University Cancer Institute and Hospital60
进行中（未招募）
2 期
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRCColorectal NeoplasmsNCT05143099Shanghai Zhongshan Hospital35